Gut Microbiota and Psoriasis: Pathogenesis, Targeted Therapy, and Future Directions

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Aug 22

PMID 39170985

Authors

Xinyan Zou

Xinfu Zou

Longxia Gao

Hanqing Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis is one of the most common autoimmune skin diseases. Increasing evidence shows that alterations in the diversity and function of microbiota can participate in the pathogenesis of psoriasis through various pathways and mechanisms.

Objective: To review the connection between microbial changes and psoriasis, how microbial-targeted therapy can be used to treat psoriasis, as well as the potential of prebiotics, probiotics, synbiotics, fecal microbiota transplantation, diet, and Traditional Chinese Medicine as supplementary and adjunctive therapies.

Methods: Literature related to the relationship between psoriasis and gut microbiota was searched in PubMed and CNKI.

Results: Adjunct therapies such as dietary interventions, traditional Chinese medicine, and probiotics can enhance gut microbiota abundance and diversity in patients with psoriasis. These therapies stimulate immune mediators including IL-23, IL-17, IL-22, and modulate gamma interferon (IFN-γ) along with the NF-kB pathway, thereby suppressing the release of pro-inflammatory cytokines and ameliorating systemic inflammatory conditions.

Conclusion: This article discusses the direction of future research and clinical treatment of psoriasis from the perspective of intestinal microbiota and the mechanism of traditional Chinese medicine, so as to provide clinicians with more comprehensive diagnosis and treatment options and bring greater hope to patients with psoriasis.

Citing Articles

Chinese medicine as comprehensive therapy for psoriasis: A case report.

Liu L, Li M, Hu M, Ge Z, Dong X Medicine (Baltimore). 2024; 103(48):e40747.

PMID: 39612407 PMC: 11608678. DOI: 10.1097/MD.0000000000040747.

References

Zhang C, Wang H, Chen T . Interactions between Intestinal Microflora/Probiotics and the Immune System. Biomed Res Int. 2019; 2019:6764919. PMC: 6886316. DOI: 10.1155/2019/6764919. View

Sugihara K, Kamada N . Diet-Microbiota Interactions in Inflammatory Bowel Disease. Nutrients. 2021; 13(5). PMC: 8147260. DOI: 10.3390/nu13051533. View

Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M . Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298(7):321-8. DOI: 10.1007/s00403-006-0703-z. View

Xiao S, Zhang G, Jiang C, Liu X, Wang X, Li Y . Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing. Front Cell Infect Microbiol. 2021; 11:605825. PMC: 8047475. DOI: 10.3389/fcimb.2021.605825. View

Gantenbein K, Kanaka-Gantenbein C . Mediterranean Diet as an Antioxidant: The Impact on Metabolic Health and Overall Wellbeing. Nutrients. 2021; 13(6). PMC: 8227318. DOI: 10.3390/nu13061951. View

Wang X, Chen Z, Qiao S, Zhu Q, Zuo Z, Guo B . Analysis of Alterations of the Gut Microbiota in Moderate to Severe Psoriasis Patients Using 16S rRNA Gene Sequencing. Indian J Dermatol. 2023; 67(5):495-503. PMC: 9971763. DOI: 10.4103/ijd.ijd_297_22. View

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz I, Kurtzman D . A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque.... J Dermatolog Treat. 2018; 29(6):569-578. DOI: 10.1080/09546634.2017.1422591. View

Sun L, Liu W, Zhang L . The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis. J Immunol Res. 2019; 2019:1824624. PMC: 6877906. DOI: 10.1155/2019/1824624. View

Kragsnaes M, Kjeldsen J, Horn H, Munk H, Pedersen F, Holt H . Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open. 2018; 8(4):e019231. PMC: 5922473. DOI: 10.1136/bmjopen-2017-019231. View

10.

Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A . Gut Microbiome in Psoriasis: An Updated Review. Pathogens. 2020; 9(6). PMC: 7350295. DOI: 10.3390/pathogens9060463. View

11.

Shin N, Whon T, Bae J . Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015; 33(9):496-503. DOI: 10.1016/j.tibtech.2015.06.011. View

12.

Fusco W, Lorenzo M, Cintoni M, Porcari S, Rinninella E, Kaitsas F . Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 2023; 15(9). PMC: 10180739. DOI: 10.3390/nu15092211. View

13.

Hosseini A, Razavi B, Banach M, Hosseinzadeh H . Quercetin and metabolic syndrome: A review. Phytother Res. 2021; 35(10):5352-5364. DOI: 10.1002/ptr.7144. View

14.

Li X, Chen Y, Dai G, Zhou B, Yan X, Tan R . Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. J Ethnopharmacol. 2021; 272:113934. DOI: 10.1016/j.jep.2021.113934. View

15.

Zhang X, Shi L, Sun T, Guo K, Geng S . Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. BMC Microbiol. 2021; 21(1):78. PMC: 7941898. DOI: 10.1186/s12866-021-02125-1. View

16.

Albanesi C, Madonna S, Gisondi P, Girolomoni G . The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front Immunol. 2018; 9:1549. PMC: 6043636. DOI: 10.3389/fimmu.2018.01549. View

17.

Calder P . Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017; 45(5):1105-1115. DOI: 10.1042/BST20160474. View

18.

Cao W, Wang C, Chin Y, Chen X, Gao Y, Yuan S . DHA-phospholipids (DHA-PL) and EPA-phospholipids (EPA-PL) prevent intestinal dysfunction induced by chronic stress. Food Funct. 2018; 10(1):277-288. DOI: 10.1039/c8fo01404c. View

19.

Moludi J, Khedmatgozar H, Saiedi S, Razmi H, Alizadeh M, Ebrahimi B . Probiotic supplementation improves clinical outcomes and quality of life indicators in patients with plaque psoriasis: A randomized double-blind clinical trial. Clin Nutr ESPEN. 2021; 46:33-39. DOI: 10.1016/j.clnesp.2021.09.004. View

20.

Lubberts E, Scher J, FitzGerald O . Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis. J Rheumatol. 2022; 49(6 Suppl 1):16-19. DOI: 10.3899/jrheum.211321. View